Publications by authors named "Luca Frison"

Claim this Profile
A
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements.
Massimiliano Bonifacio, Luigi Scaffidi, Maria Cristina Miggiano, Davide Facchinelli, Luca Tosoni, Luca Frison

Blood Cancer J· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia.
Giovanni Martinelli, Cristina Papayannidis, Alfonso Piciocchi, Valentina Robustelli, Simona Soverini, Luca Frison

Blood Adv· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphoblastic Lymphoma: a Concise Review.
Tamara Intermesoli, Alessandra Weber, Matteo Leoncin, Luca Frison, Cristina Skert

Curr Oncol Rep· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL.
Manuela Tosi, Orietta Spinelli, Matteo Leoncin, Roberta Cavagna, Chiara Pavoni, Luca Frison

Cancers (Basel)· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relevance of antiphospholipid antibody profile in the clinical outcome of ITP: a single-centre study.
Luca Frison, Annamaria Lombardi, Ilaria Caputo, Gianpietro Semenzato, Fabrizio Fabris

Hematology· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Myeloid Leukemia With Myelofibrosis-Like Features. Clues of Accelerated Phase?
Gianni Binotto, Roberta Bertorelle, Laura Bonaldi, Luca Frison, Fabrizio Vianello

Int J Surg Pathol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy.
Massimiliano Bonifacio, Luigi Scaffidi, Gianni Binotto, Maria Cristina Miggiano, Marco Danini, Luca Frison

Leuk Res· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients.
Mario Tiribelli, Massimiliano Bonifacio, Gianni Binotto, Alessandra Iurlo, Francesca Cibien, Luca Frison

Oncotarget· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
Massimiliano Bonifacio, Gianni Binotto, Elena Maino, Elisabetta Calistri, Luciana Marin, Luca Frison

Haematologica· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis